Drugs / Umbilical Cord-derived Wharton's Jelly
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04719793 | Jan 2023 → Dec 2024 | osteoarthritis, knee | BioIntegrate | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04424394 | Jan 2023 → Dec 2024 | erectile dysfunction | BioIntegrate | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical cord-derived Wharton's Jelly | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04424394 ↗ |
| Known as | UC-derived WJ | “To combat this process, the use of biologics including umbilical cord-derived Wharton's Jelly (UC-derived WJ) has grown.” PMID 33602286 ↗ Feb 2021 |
| Route | Other | “2 intracavernosal injections over a period of 7 weeks.” NCT04424394 ↗ |